Here at GeneFirst, we pride ourselves on the innovative technologies that go into making our solutions.
GeneFirst's MPA technology overcomes the limit on real-time PCR multiplexing and allows differentiation of up to six different targets per fluorescence channel.
GeneFirst’s proprietary MMD-PCR technology is real-time PCR-based and intended for detection of cancer-associated mutations in DNA.
ATOM-seq™ reduces error rates associated with sequencing, and is suitable for detecting rare mutations in blood-borne ctDNA.
With at least 10-fold increase in sensitivity than conventional PCR, PCDR produces twice as much material in each round of thermal cycling.